Today on Clinical Trials Day, Bold Therapeutics, in partnership with N2 Canada, proudly stands alongside our colleagues, partners, and patients in recognizing the vital role of clinical research in advancing global health.
Clinical trials—whether early-phase or pivotal late-stage studies—are the backbone of medical progress. None of it would be possible without the dedication of investigators, research staff, and the incredible patients and families who place their trust in evidence-based science.
At Bold Therapeutics, we are committed to developing safer, more effective treatments that improve patient outcomes and transform the standard of care. Bold Therapeutics is currently enrolling FOLFOX-naïve second-line mCRC patients in a multinational randomized clinical study comparing FOLFOX vs. FOLFOX + BOLD-100 in various efficacy, safety, and quality-of-life endpoints. Bold Therapeutics anticipates this trial will further demonstrate BOLD-100's potential as a transformative therapy in early-line colorectal cancer, biliary tract cancer and other solid tumour indications. To learn more visit (ADD Clinical Trial link for second-line trial)
To everyone participating in or driving innovation through clinical research,
Thank you.
